ESPR — Esperion Therapeutics, Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for ESPR in the TickerWise workspace.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Company profile

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Country: US
• Exchange: NASDAQ
• Employees: 304
• Website: https://www.esperion.com

Latest SEC filings for ESPR

• 2026-07-2315-12G
• 2026-07-16EFFECT
• 2026-07-16EFFECT
• 2026-07-16EFFECT
• 2026-07-16EFFECT
• 2026-07-16EFFECT
• 2026-07-16EFFECT
• 2026-07-14SCHEDULE 13G/A
• 2026-07-13S-8 POS
• 2026-07-13S-8 POS

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.